Exciva GmbH
PrivateLast Round
Series B
Jan 20, 2026
Total Funding Raised
$59.4M
Company Overview
Exciva GmbH is a biopharmaceutical company developing new therapeutic compounds for the treatment of neuropsychiatric conditions, with a focus on agitation in patients with Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exciva GmbH Comps
Public and private peers based on sector, stage, and business model.
Exciva GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 20, 2026 |
Exciva GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| Gimv | Series B |
| Andera Partners | Series B |
| Fountain Healthcare Partners | Series B |
| Landesbank Baden-Württemberg | Series B |
| LifeArc Ventures | Series B |
| LifeArc | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 20, 2026
$59M round completed.
- Jun 1, 2025
Monthly visitors grew 63% MoM, from 319 to 521.
Exciva GmbH Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Exciva GmbH's valuation, stock price, and market status.
